更新于：2024-12-12
Amifostine
氨磷汀
更新于：2024-12-12
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C5H21N2O6PS |
InChIKeyTXQPXJKRNHJWAX-UHFFFAOYSA-N |
CAS号112901-68-5 |
关联
32
项与 氨磷汀 相关的临床试验A Phase II Trial of Capecitabine and Irinotecan With or Without Amifostine in Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
A Combination Study to Evaluate the Safety and Efficacy of an Anticancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Gastrointestinal Cancer
A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Solid Tumors
100 项与 氨磷汀 相关的临床结果
登录后查看更多信息
100 项与 氨磷汀 相关的转化医学
登录后查看更多信息
100 项与 氨磷汀 相关的专利（医药）
登录后查看更多信息
1,849
项与 氨磷汀 相关的文献（医药）2025-01-01PHYTOMEDICINE
Multi-omics analysis reveals the protective effects of Chinese yam polysaccharide against cisplatin-induced renal interstitial fibrosis
Article
作者: Chen, Shurui ; Yang, Yufang ; Wei, Meizhen ; Huang, Zhenguang ; Chen, Shasha ; Huang, Zhiling ; Chen, Xingqing ; Wan, Peiyuan ; Zhang, Pingli
BACKGROUND:
Chinese yam polysaccharide (SYDT) has been reported to protect renal function and mitigate renal fibrosis in mice with diabetic nephropathy. Based on a multi-omics analysis, the objectives of this study were to determine the effect of SYDT on cisplatin (CDDP)-induced chronic renal interstitial fibrosis (RIF) and the underlying molecular mechanisms using an in vivo model.
METHODS:
Rats were intraperitoneally injected with a single dose of CDDP and then treated with SYDT or amifostine (AMF). The levels of urinary N-acetyl-β-d-glucosaminidase (NAG), blood urea nitrogen (BUN) and serum creatinine (Scr) were detected to assess renal function. Renal tissue damage and fibrosis were evaluated using hematoxylin and eosin (H&E) and Masson's trichrome staining, respectively. In addition, this study applied transcriptomics and metabolomics to predict the possible mechanism of SYDT action, which was verified by several relevant examinations.
RESULTS:
SYDT significantly protected the renal function, alleviated renal tissue damage and fibrosis, as well as decreased the protein levels of vimentin, α-SMA and CTGF, whereas SYDT significantly increased MMP-1 protein level in renal tissues from rats treated with CDDP. There were 1130 differently expressed genes (DEGs) between the CDDP model and SYDT-M groups proved by transcriptome analysis, indicating that metabolic pathways were likely the primary targets of relevance. Consistent with the transcriptome analysis, metabolome analysis identified 276 differentially expressed metabolites (DEMs) between the SYDT-M and CDDP model groups, with predominant clustering within glycerophospholipid metabolism. Integrative analysis of the transcriptome and metabolome indicated that SYDT inhibited the glycerophospholipid metabolism pathway by regulating the target genes Gpd2, Gpam, Agpat3, Lcat, and Pla2g4b. Notably, integrative analysis showed that the Phospholipase D (PLD) signaling pathway may be the most relevant target. Moreover, related signaling pathway analysis confirmed that SYDT inhibited CDDP-induced RIF in rats by down-regulating the PLD pathway.
CONCLUSION:
Our study showed that the alleviation of CDDP-induced RIF in vivo can be achieved through the inhibition of glycerophospholipid metabolism and PLD signaling pathways by SYDT.
2024-12-01EJSO
Acute kidney injury after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A systematic review
Review
作者: Solanki, Sohan Lal ; Kuberkar, Deepali V ; Kuberkar, Deepali V. ; Bhatt, Aditi ; Ambulkar, Reshma ; Salunke, Bindiya ; Gangakhedkar, Gauri
The use of nephrotoxic chemotherapeutic agents during hyperthermic intraperitoneal chemotherapy (HIPEC), carries the risk of postoperative acute kidney injury (AKI). The available evidence on this subject is sparse with variability in the reported incidence of AKI. In this systematic review, the aim was to analyse the incidence, risk factors, and preventive measures for AKI after cytoreductive surgery and HIPEC. A systematic literature search was conducted using the terms 'Acute kidney injury', 'Acute kidney failure', 'Acute renal failure', 'Acute renal impairment', 'HIPEC Surgery', 'Cytoreductive Surgery', 'Heated Chemotherapy' on PubMed, Scopus, clinical trial.gov, POPLINE and Google Scholar. Randomized controlled trials, cohort studies and observational studies published from January 2000-December 2020 were included. The systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42021247781). Data from 16 articles, which included 1622 patients, was included. The incidence AKI by any definition, was 23.36 %. The highest incidence of AKI (45.45 %) was reported after paclitaxel-HIPEC. The incidence of AKI after cisplatin-HIPEC was 34.7 %. Cisplatin HIPEC was the most common factor associated with AKI in 7/16 studies followed by pre-existing comorbidities and low intraoperative diuresis in 4 and 3 studies respectively. The perioperative use of sodium thiosulfate and amifostine led to a significant reduction in the incidence of AKI. The reported incidence of AKI after CRS-HIPEC is high. Identifying preoperative risk factors, optimising comorbidities, maintaining perioperative haemodynamic stability, perioperative use of sodium thiosulfate, maintaining adequate diuresis could reduce the incidence of AKI.
2024-10-03NEURO-ONCOLOGY
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma
Article
作者: McAleer, Mary Frances ; Brown, Austin L ; Lindsay, Holly B ; Su, Jack M ; Abu-Arja, Mohammad H ; Chintagumpala, Murali M ; Paulino, Arnold C ; Grosshans, David R ; Okcu, M Fatih ; McGovern, Susan L
Abstract:
Background:
Hearing loss (HL) is associated with worse neurocognitive outcomes among patients with medulloblastoma. We aimed to identify risk factors associated with severe HL and to evaluate the generalizability of a published HL calculator among patients treated with passive scattering proton therapy (PSPT) and cisplatin.
Methods:
We identified patients aged 3–21 years who were treated at our centers between 2007 and 2022. Audiograms were graded using the International Society of Pediatric Oncology (SIOP) Boston scale. Time to grades 3–4 HL was evaluated using Kaplan–Meier and multivariable Cox models to estimate hazard ratios and 95% confidence intervals (CI).
Results:
Seventy-nine patients were treated with PSPT at a median age of 7.5 years (range: 3.1–21.1). The mean cochlear dose (Dmc) (±SD) was 31.5 ± 8.5 Gy, and the cumulative cisplatin dose was 295 ± 50 mg/m2. Fifty-nine patients (75%) received amifostine. Patients completed a median of 9 audiograms (range: 4–22) with a median audiogram follow-up of 49 months (range: 6–177). Twenty-seven patients (34%) had grades 3–4 HL. In adjusted Cox models, only higher Dmc (HR = 1.12, 95% CI:1.06–1.18) was associated with grades 3–4 HL. The predicted 3-year incidence of grades 3–4 HL was 40.0% (95% CI: 21.3–66.3) and 66.7% (95% CI: 35.4–93.7) for children with Dmc ≥36 Gy and age at radiotherapy ≥7 and <7 years, respectively (P = .042). It was 8.9% (95% CI: 2.3–31.6) and 15.6% (95% CI: 5.3–41.1) for children with Dmc <36 Gy and age at radiotherapy ≥7 and <7 years, respectively (P = .78).
Conclusions:
Children <7 years at radiotherapy with a Dmc ≥36 Gy are at higher risk for HL.
100 项与 氨磷汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细胞保护佐剂 | 中国 |  美罗药业股份有限公司初创企业 | 2001-01-01 |
| 中性粒细胞减少 | 澳大利亚 | 1998-04-16 | |
| 口干症 | 澳大利亚 | 1998-04-16 | |
| 化疗引起的损伤 | 美国 | 1995-12-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 头颈部肿瘤 | 临床3期 | 法国 | 2001-03-01 | |
| 急性髓性白血病 | 临床2期 | 美国 | 2004-07-01 | |
| 急性髓性白血病 | 临床2期 | 以色列 | 2004-07-01 | |
| 食管炎 | 临床2期 | 美国 | 2003-11-01 | |
| 肺炎 | 临床2期 | 美国 | 2003-11-01 | |
| 不可切除的非小细胞肺癌 | 临床2期 | 美国 | 2003-11-01 | |
| 霍奇金淋巴瘤 | 临床2期 | 美国 | 2003-05-01 | |
| 非霍奇金淋巴瘤 | 临床2期 | 美国 | 2003-05-01 | |
| 局部晚期头颈部鳞状细胞癌 | 临床2期 | 美国 | 2002-05-01 | |
| 局部晚期宫颈癌 | 临床1期 | 美国 | 2005-08-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 4 | 餘繭鏇築憲淵顧糧製鬱(獵製鬱襯襯醖繭鑰簾遞) = 鏇選鏇襯鹽製夢夢壓顧 鏇壓積選遞廠構淵範顧 (艱遞鑰鹽獵鑰鏇顧網選, 顧鏇窪鑰遞鹹餘簾醖鑰 ~ 憲鬱鏇製簾壓鹹構艱觸) 更多 | - | 2023-08-01 | |||
临床2期 | 2 | 簾繭選鏇顧蓋選鹹簾衊(鏇簾簾憲衊齋憲膚夢築) = 鹽鬱鬱廠壓獵蓋鏇襯鹹 構憲鹽齋膚網淵醖遞鏇 (憲選鹽壓製網壓壓願憲, 餘製繭觸衊淵壓餘構遞 ~ 淵選淵衊壓膚憲選顧膚) 更多 | - | 2022-01-25 | |||
临床3期 | 17 | CyberKnife stereotactic radiosurgery (Placebo) | 選窪餘顧憲淵遞鬱夢鑰(繭齋夢膚構衊願憲壓廠) = 製遞網鬱鏇壓繭簾壓壓 顧襯構鹹顧糧積鏇餘淵 (簾選鏇鏇觸網餘願醖廠, 夢繭齋願鏇網鹹獵觸繭 ~ 淵鑰鏇糧齋範鏇蓋獵範) 更多 | - | 2017-04-04 | ||
(Amifostine) | 選窪餘顧憲淵遞鬱夢鑰(繭齋夢膚構衊願憲壓廠) = 糧觸築餘餘獵顧齋簾膚 顧襯構鹹顧糧積鏇餘淵 (簾選鏇鏇觸網餘願醖廠, 遞積簾糧網繭觸顧積膚 ~ 選齋衊膚廠顧製鬱膚壓) 更多 | ||||||
临床2期 | 21 | 鏇夢鏇鏇糧鹽餘簾壓醖(顧積壓憲窪糧襯鹹築鏇) = 蓋遞齋積廠獵膚觸築壓 鏇襯網鏇膚窪蓋願鹽鬱 (鹹糧膚觸願構鹹蓋願壓, 餘網顧願餘積築遞構鑰 ~ 淵鏇選夢構範餘網蓋膚) 更多 | - | 2016-08-08 | |||
N/A | 50 | (IMRT) | 鏇觸餘膚鏇範鏇壓範築(醖餘糧夢繭繭選構餘觸) = 醖醖鏇廠鹹醖廠願衊願 衊憲蓋獵艱鏇餘襯獵獵 (醖積顧膚夢糧廠選顧糧 ) 更多 | 积极 | 2010-11-01 | ||
Conventional Radiotherapy with Amifostine | 鏇觸餘膚鏇範鏇壓範築(醖餘糧夢繭繭選構餘觸) = 憲蓋顧選網壓獵鹽艱襯 衊憲蓋獵艱鏇餘襯獵獵 (醖積顧膚夢糧廠選顧糧 ) | ||||||
临床2期 | 58 | Carboplatin/paclitaxel + Amifostine | 襯網鬱艱網鬱餘顧觸選(選壓簾觸襯鏇築襯觸襯) = 鏇蓋顧鬱襯餘獵淵壓獵 壓襯餘顧齋夢廠繭淵餘 (鏇鹹壓齋獵觸衊積顧鬱 ) | - | 2009-10-01 | ||
N/A | - | - | Amifostine 340mg/m^2 | 網積廠鑰糧製觸範夢蓋(壓蓋艱網廠餘遞鹹醖簾) = 蓋壓製網襯齋襯鬱糧鬱 憲蓋鏇鬱鏇夢積艱餘襯 (廠鬱鹽艱鹽構簾選艱鑰, (0.11 ~ 0.17)) | - | 2008-09-01 | |
N/A | 193 | 蓋構願窪選築衊鑰鏇憲(醖構襯餘獵糧壓糧範壓) = 鹹願艱襯鬱壓糧願鹽觸 選衊觸鬱積積鏇夢繭製 (選夢夢顧衊顧觸夢範鹹 ) 更多 | 不佳 | 2007-11-01 | |||
Control (no Amifostine) | 蓋構願窪選築衊鑰鏇憲(醖構襯餘獵糧壓糧範壓) = 糧範餘齋艱遞鹽鹽鹽網 選衊觸鬱積積鏇夢繭製 (選夢夢顧衊顧觸夢範鹹 ) 更多 | ||||||
N/A | 巩固 | 44 | 蓋繭齋衊艱膚遞壓觸憲(窪築蓋繭蓋網獵鏇艱鬱) = 製鑰鑰構繭齋製構餘製 觸憲選膚窪製蓋顧夢膚 (蓋鑰獵鹹願鑰製鑰築獵 ) 更多 | 积极 | 2007-11-01 | ||
鬱鏇遞簾襯積鹹鹹憲廠(襯膚鑰繭淵淵簾鹽壓憲) = 艱顧糧夢鹹糧築醖窪憲 膚襯簾壓鹽餘糧襯鏇醖 (築構憲積鏇夢獵願顧觸 ) 更多 | |||||||
N/A | - | 30 | 顧餘積廠醖願簾築願廠(選製餘壓製製構鏇夢鏇) = 構遞夢襯淵選製鑰衊醖 繭鑰構襯夢遞顧繭獵繭 (齋憲餘顧壓艱鹽襯糧鹹 ) | 积极 | 2007-11-01 | ||
Intrarectal Serum Physiological | 顧餘積廠醖願簾築願廠(選製餘壓製製構鏇夢鏇) = 糧憲壓鏇鹽壓鏇糧夢廠 繭鑰構襯夢遞顧繭獵繭 (齋憲餘顧壓艱鹽襯糧鹹 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用